期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 55, 期 9, 页码 4427-4429出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00104-11
关键词
-
资金
- National Institutes of Health [5R44 AI 63692-04]
Fidaxomicin (FDX), a narrow-spectrum antibiotic recently shown to be superior to vancomycin in providing sustained clinical response to Clostridium difficile infection, was investigated along with its major metabolite, OP-1118, with regard to their postantibiotic effects (PAE). FDX was found to have a prolonged PAE (10 h versus ATCC strains and 5.5 h versus a clinical isolate), and OP-1118's PAE was longer than that of the standard comparator, vancomycin (3 versus 0 to 1.5 h, respectively).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据